Literature DB >> 19750179

The pharmacological management of migraine, part 2: preventative therapy.

George Demaagd.   

Abstract

Entities:  

Year:  2008        PMID： 19750179      PMCID： PMC2730105     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  153 in total

1.  Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study.

Authors:  G Sances; E Martignoni; L Fioroni; F Blandini; F Facchinetti; G Nappi
Journal:  Headache       Date:  1990-11       Impact factor: 5.887

2.  EFNS guideline on the drug treatment of migraine - report of an EFNS task force.

Authors:  S Evers; J Afra; A Frese; P J Goadsby; M Linde; A May; P S Sándor
Journal:  Eur J Neurol       Date:  2006-06       Impact factor: 6.089

3.  Magnesium in the prophylaxis of migraine--a double-blind placebo-controlled study.

Authors:  V Pfaffenrath; P Wessely; C Meyer; H R Isler; S Evers; K H Grotemeyer; Z Taneri; D Soyka; H Göbel; M Fischer
Journal:  Cephalalgia       Date:  1996-10       Impact factor: 6.292

4.  Botulinum toxin type A in prophylactic treatment of migraine.

Authors:  K S Anand; Atul Prasad; M M Singh; Sangeeta Sharma; Kiran Bala
Journal:  Am J Ther       Date:  2006 May-Jun       Impact factor: 2.688

5.  Efficacy of gabapentin in migraine prophylaxis.

Authors:  N T Mathew; A Rapoport; J Saper; L Magnus; J Klapper; N Ramadan; B Stacey; S Tepper
Journal:  Headache       Date:  2001-02       Impact factor: 5.887

6.  Nefazodone for chronic daily headache prophylaxis: an open-label study.

Authors:  J R Saper; A E Lake; S J Tepper
Journal:  Headache       Date:  2001-05       Impact factor: 5.887

7.  Age-dependent prevalence and clinical features of migraine.

Authors:  Marcelo E Bigal; Joshua N Liberman; Richard B Lipton
Journal:  Neurology       Date:  2006-07-25       Impact factor: 9.910

8.  Long-term migraine prevention with topiramate: open-label extension of pivotal trials.

Authors:  Alan Rapoport; Alexander Mauskop; Hans-Christoph Diener; Susanne Schwalen; Joop Pfeil
Journal:  Headache       Date:  2006 Jul-Aug       Impact factor: 5.887

9.  Open-label, long-term tolerability of naratriptan for short-term prevention of menstrually related migraine.

Authors:  Jan Lewis Brandes; Timothy Smith; Merle Diamond; Michael H Ames
Journal:  Headache       Date:  2007-06       Impact factor: 5.887

10.  Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.

Authors:  H-C Diener; G Bussone; J C Van Oene; M Lahaye; S Schwalen; P J Goadsby
Journal:  Cephalalgia       Date:  2007-04-18       Impact factor: 6.292
View more
  4 in total

1.  Cost effectiveness of pharmacotherapy for the prevention of migraine: a Markov model application.

Authors:  Junhua Yu; Kenneth J Smith; Diana I Brixner
Journal:  CNS Drugs       Date:  2010-08       Impact factor: 5.749

2.  Effect of Different Meditation Types on Migraine Headache Medication Use.

Authors:  Amy B Wachholtz; Christopher D Malone; Kenneth I Pargament
Journal:  Behav Med       Date:  2015-04-11       Impact factor: 3.104

3.  Comparative efficacy trial of cupping and serkangabin versus conventional therapy of migraine headaches: A randomized, open-label, comparative efficacy trial.

Authors:  Mohammad Dehghani Firoozabadi; Maryam Navabzadeh; Mohammad Khodashenas Roudsari; Mohsen Zahmatkash
Journal:  J Res Med Sci       Date:  2014-12       Impact factor: 1.852

4.  Ketorolac versus Magnesium Sulfate in Migraine Headache Pain Management; a Preliminary Study.

Authors:  Hossein Delavar Kasmaei; Marzieh Amiri; Ahmed Negida; Samaneh Hajimollarabi; Nastaransadat Mahdavi
Journal:  Emerg (Tehran)       Date:  2017-01-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.